PeDRA Partners

Standardized treatment protocols and clinical guidelines are sorely lacking for pediatric skin disorders, including some conditions that are truly life threatening. Yet recruiting children for studies is challenging, and trials are often underpowered, especially with rare diseases. With this reality, pediatric dermatology leaders recognized in 2012 that investigations could not make meaningful progress without collaborative efforts.

Sponsorship Opportunities

Conference_Lobby

The Pediatric Dermatology Research Alliance (PeDRA) is a collaborative research network, a novel and innovative organization advancing scientific investigations in pediatric dermatology. There is no other dermatology organization that specifically aims toaccelerate research in pediatric skin diseases. With investigators from nearly 70 institutions working together, PeDRA fosters multisite research initiatives involving scientists, clinicians, trainees, study design experts and patient advocacy representatives.

For information on becoming a PeDRA sponsor, please contact Sheila Rittenberg, PeDRA Executive Director.

Early on, PeDRA leaders established the PeDRA Annual Conference, a research meeting that organizes multicenter studies in all major areas of pediatric dermatology – large-scale research initiatives that provide biologic insight into and/or advance clinical care of childhood skin disease. The Conference sets research priorities and provides a platform from which basic science, clinical, and translational collaborative studies develop. It is partially funded by the National Institutes of Health (NIH), and further supported by industry and patient advocacy organizations.

Conference_Speaker

For information on becoming a PeDRA Annual Conference sponsor, please contact Sheila Rittenberg, PeDRA Executive Director.

An excerpt of the 2015 Conference program is here for your viewing.
Check this page in the coming months for a posting of new policies, or contact Sheila Rittenberg.
Please review PeDRA Industry Guidelines for an understanding of how we work with industry.

An excerpt of the 2015 Conference program is here for your viewing.
Check this page in the coming months for a posting of new policies, or contact Sheila Rittenberg.

Please review PeDRA Industry Guidelines for an understanding of how we work with industry.

Current & past PeDRA funders

PeDRA owes a debt of thanks to the many individuals, advocacy organizations, and pharmaceutical/ biomedical companies that support PeDRA. They have significantly helped the Alliance by providing foundational funding, and enabling the growth and expansion of the organization.

PeDRA graciously thanks and acknowledges the Society for Pediatric Dermatology (SPD)  for its unwavering support of research. The Society’s commitment to launching PeDRA and shepherding of the Alliance as an entity completely dedicated to research is the reason we are now seeing important studies emerging under the PeDRA umbrella. PeDRA operates as a research arm of SPD.

OUR FUNDERS:

National Institutes of Health

Patient Advocacy Organizations:

alopecia_areata                 costello                  eb_mrf

ebresearchpartners                first                  npf-logo-horz-web

nevusoutreach                parentseczema                phace

sturge-weber                   nea

CHYONYCHIA CONGENITA

Other Donors (2013 – 2015):

Gordon Dow
William D. Ginn (through the Basal Cell Carcinoma Nevus Syndrome Life Support Network)
Elly Werner, Hoefer Foundation
National Alopecia Areata Foundation

Industry Partners:

CLnThinkCC_LOGO_SilverBorder             Celgene Logo with Tagline                   P&G Pampers_teal_logo

Huggies_KC_Full_R1-01  GSK-Stiefel logo                   pfizer_rgb_pos
Anacor-Logo-CMYK_Large       ValeantNAInc_Logo_NORTH PierreFabre_Inc USE
Impression

 

1 **Funding for the PeDRA Annual Conference was made possible by a grant (R13AR068926) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The views expressed or written in conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the National Institutes of Health; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government